Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47,664,990
-
Total 13F shares
-
49,276,697
-
Share change
-
+10,776,635
-
Total reported value
-
$1,463,478,389
-
Put/Call ratio
-
72%
-
Price per share
-
$29.70
-
Number of holders
-
123
-
Value change
-
+$335,895,378
-
Number of buys
-
86
-
Number of sells
-
29
Institutional Holders of Rapport Therapeutics, Inc. - Common Stock (RAPP) as of Q3 2025
As of 30 Sep 2025,
Rapport Therapeutics, Inc. - Common Stock (RAPP) was held by
123 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
49,276,697 shares.
The largest 10 holders included
TRV GP V, LLC, FMR LLC, ARCH Venture Management, LLC, Capital International Investors, Cormorant Asset Management, LP, GOLDMAN SACHS GROUP INC, Sofinnova Investments, Inc., JOHNSON & JOHNSON, VANGUARD GROUP INC, and BlackRock, Inc..
This page lists
123
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.